

patidu i mimo jeho antidiabetické působení, z tohoto pohledu budou nyní dokončeny zásadní studie.

Vedle kardiovaskulární protektivity jsou stále více skloňovány benefiční účinky duálních agonistů receptorů pro GLP1/GIP u pacientů

s MASH a jaterní fibrózou a zejména potom nefroprotektivní účinky u pacientů s chronickým onemocněním ledvin.

Tirzepatid se zdá být tedy velmi slibnou léčbou u pacientů s DM2 a obezitou a zdá se být účinnější, než jsou agonisté izolových GLP-1 agonistů.

**PROHLÁŠENÍ AUTORŮ:** Prohlášení o původnosti: Práce je původní a nebyla publikována ani není zaslána k recenznímu řízení do jiného média. **Střet zájmů:** Žádný. **Financování:** Ne. **Poděkování:** N/A. **Registrace v databázích:** N/A. **Projednání etikou komisí:** N/A.

## LITERATURA

- Wang L. Designing a dual GLP-1R/GIPR agonist from tirzepatide: comparing residues between tirzepatide, GLP-1, and GIP. *Drug Des Devel Ther.* 2022;16:1547-1559.
- De Block C, Bailey C, Wysham C, et al. Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective. *Diabetes Obes Metab.* 2023;25(1):3-17.
- Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. *Gastroenterology.* 2007;132(6):2131-2157.
- Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept. *Molec Metab.* 2018;18:3-14.
- Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. *JCI Insight.* 2020;5(17):e140532.
- Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. *Lancet.* 2021 Jul 10;398(10295):143-155. doi: 10.1016/S0140-6736(21)01324-6.
- Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. *N Engl J Med.* 2021 Aug 5;385(6):503-515. doi: 10.1056/NEJMoa2107519. Epub 2021 Jun 25. PMID: 34170647.
- Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. *Lancet.* 2021 Aug 14;398(10300):583-598. doi: 10.1016/S0140-6736(21)01443-4. Epub 2021 Aug 6. PMID: 34370970.
- Del Prato S, Kahn SE, Pavo I, et al. SURPASS-4 Investigators. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. *Lancet.* 2021 Nov 13;398(10313):1811-1824. doi: 10.1016/S0140-6736(21)02188-7. Epub 2021 Oct 18. PMID: 34672967.
- Heerspink HJL, Sattar N, Pavo I, et al. Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial. *Lancet Diabetes Endocrinol.* 2022 Nov;10(11):774-785. doi: 10.1016/S2213-8587(22)00243-1. Epub 2022 Sep 21. PMID: 36152639.
- Dahl D, Onishi Y, Norwood P, et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. *JAMA.* 2022 Feb 8;327(6):534-545. doi: 10.1001/jama.2022.0078. PMID: 35133415; PMCID: PMC8826179.
- Rosenstock J, Frias JP, Rodbard HW, et al. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. *JAMA.* 2023;330(17):1631-1640. doi:10.1001/jama.2023.20294
- Nicholls SJ, Bhatt DL, Buse JB, et al. SURPASS-CVOT Investigators. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. *Am Heart J.* 2024 Jan;267:1-11. doi: 10.1016/j.ahj.2023. 09. 007. Epub 2023 Sep 25. PMID: 37758044.
- Jastreboff AM, Aronne LJ, et al. SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. *N Engl J Med.* 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.
- Jastreboff AM, le Roux CW, Stefanski A, et al. SURMOUNT-1 Investigators. Tirzepatide for Obesity Treatment and Diabetes Prevention. *N Engl J Med.* 2024 Nov 13. doi: 10.1056/NEJMoa2410819. Epub ahead of print. PMID: 39536238.
- Goff DC, Lloyd-Jones DM, D'Agostino RB, et al. Report on the assessment of cardiovascular risk: full work group report supplement. 2013. [http://jacccardiosource.com/acc\\_documents/2013\\_FPR\\_S5\\_Risk\\_Assesment.pdf](http://jacccardiosource.com/acc_documents/2013_FPR_S5_Risk_Assesment.pdf)
- Hankosky ER, Wang H, Neff LM, et al. Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis. *Diabetes Obes Metab.* 2024 Jan;26(1):319-328. doi: 10.1111/dom.15318. Epub 2023 Nov 6. PMID: 37932236.
- Garvey WT, Frias JP, Jastreboff AM, et al. SURMOUNT-2 investigators. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet.* 2023 Aug 19;402(10402):613-626. doi: 10.1016/S0140-6736(23)01200-X. Epub 2023 Jun 26. PMID: 37385275.
- Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. *Nat Med.* 2023 Nov;29(11):2909-2918. doi: 10.1038/s41591-023-02597-w. Epub 2023 Oct 15. Erratum in: *Nat Med.* 2024 Jun;30(6):1784. doi: 10.1038/s41591-024-02883-1. PMID: 37840095; PMCID: PMC10667099.
- Aronne LJ, Sattar N, Horn DB, et al. SURMOUNT-4 Investigators. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. *JAMA.* 2024 Jan 2;331(1):38-48. doi: 10.1001/jama.2023.24945. PMID: 38078870; PMCID: PMC10714284.
- Guo X, Lei M, Zhao J, et al. Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats. *Front Pharmacol.* 2023;14:1146960. <https://doi.org/10.3389/fphar.2023.1146960>.
- Malhotra A, Grunstein RR, Fietze I, et al. SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. *N Engl J Med.* 2024 Oct 3;391(13):1193-1205. doi: 10.1056/NEJMoa2404881. Epub 2024 Jun 21. Erratum in: *N Engl J Med.* 2024 Oct 17;391(15):1464. doi: 10.1056/NEJMx240005. PMID: 38912654; PMCID: PMC11598664.
- Quddos F, Hubshman Z, Tegge A, et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. *Sci Rep.* 2023 Nov 28;13(1):20998. doi: 10.1038/s41598-023-48267-2. PMID: 38017205; PMCID: PMC1068450.
- Loomba R, Hartman ML, Lawitz EJ, et al. SYNERGY-NASH Investigators. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. *N Engl J Med.* 2024 Jul 25;391(4):299-310. doi: 10.1056/NEJMoa2401943. Epub 2024 Jun 8. PMID: 38856224.
- Standarts in Care of Diabetes: [https://diabetesjournals.org/care/article/48/Supplement\\_1/S6/157564/Summary-of-Revisions-Standards-of-Care-in-Diabetes](https://diabetesjournals.org/care/article/48/Supplement_1/S6/157564/Summary-of-Revisions-Standards-of-Care-in-Diabetes).
- 2020: Doporučený postup péče o diabetes mellitus 2. typu + příloha Algoritmus terapie. Available from [www.diab.cz/standarty](http://www.diab.cz/standarty).
- Standards of medical care in diabetes – 2022 abridged for primary care providers. *Diabetes.* 2022;40(1):10-38.
- Mounjaro 2,5 mg injekční roztok v předplněném peru. Mounjaro 5 mg injekční roztok v předplněném peru. Mounjaro 7,5 mg injekční roztok v předplněném peru. Mounjaro 10 mg injekční roztok v předplněném peru. Souhrn údajů o přípravku. Available from [https://www.ema.europa.eu/cs/documents/product-information/mounjaro-epar-product-information\\_cs.pdf](https://www.ema.europa.eu/cs/documents/product-information/mounjaro-epar-product-information_cs.pdf).